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ABSTRACT
Introduction Acute pulmonary embolism (PE) remains 
a common cause for morbidity and mortality in patients 
over 65 years. Given the increased risk of bleeding in the 
elderly population with the use of systemic thrombolysis, 
catheter- directed therapy (CDT) is being increasingly used 
for the treatment of submassive PE. Nevertheless, the 
safety of CDT in the elderly population is not well studied. 
We, therefore, aimed to evaluate the safety of CDT in our 
elderly patients.
Methods We conducted a retrospective observational 
study of consecutive patients aged >65 years with a 
diagnosis of PE from our Pulmonary Embolism Response 
Team database. We compared the treatment outcomes 
of CDT versus anticoagulation (AC) in elderly. Propensity 
score matching was used to construct two matched 
cohorts for final outcomes analysis.
Results Of 346 patients with acute PE, 138 were >65 
years, and of these, 18 were treated with CDT. Unmatched 
comparison between CDT and AC cohorts demonstrated 
similar in- hospital mortality (11.1% vs 5.6%, p=0.37) 
and length of stay (LOS) (3.81 vs 5.02 days, p=0.5395), 
respectively. The results from the propensity- matched 
cohort mirrored results of the unmatched cohort with no 
significant difference between CDT and AC in- hospital 
mortality (11.8% vs 5.9%, p=0.545) or median LOS (3.76 
vs 4.21 days, p=0.77), respectively.
Conclusion In this observational study using propensity 
score- matched analysis, we found that patients >65 years 
who were treated with CDT for management of acute PE 
had similar mortality and LOS compared with those treated 
with AC. Further studies are required to confirm these 
findings.
INTRODUCTION
Elderly patients aged ≥65 years are at an 
increased risk for pulmonary embolism 
(PE) and also have high mortality rates and 
bleeding risk after systemic anticoagulation 
(AC) compared with younger patients.1–3 
Moreover, treatment with systemic throm-
bolysis is associated with higher risk of major 
bleeding (13% vs 3%) and intracranial haem-
orrhage (1.4% vs 0.5%).1 4–6 Catheter- directed 
thrombolysis (CDT) is an effective method 
of treatment of intermediate- risk PE with a 
rapid reduction in right ventricle (RV) to left 
ventricle ratio and mean pulmonary artery 
systolic pressure with an excellent safety 
profile in relatively younger cohort.7–10 In this 
observational study, we evaluated the safety of 
CDT therapy in the elderly cohort compared 
with standard AC first with univariate analysis 
and then using propensity score matching. We 
hypothesise that CDT therapy is not inferior 
in safety (bleeding risk, mortality) compared 
with that of AC in elderly cohort.
METHODS
We retrospectively reviewed the data of 346 
consecutive patients with acute PE collected 
from September 2017 to June 2019 in the 
Temple University Hospital Pulmonary Embo-
lism Response Team (PERT) registry with 
approved review board protocol 26 021. We 
then selected all patients aged ≥65 years and 
excluded patients who underwent systemic 
thrombolysis, mechanical and surgical 
embolectomy. We then compared the clin-
ical outcomes of patients treated with CDT 
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to those treated with AC therapy with univariate analysis 
and then with propensity matching.
The treatment decision to proceed with CDT or other 
interventions was made by a multidisciplinary PERT. 
Major bleeding was evaluated and defined using the 
International Society on Thrombosis and Hemostasis 
(ISTH) criteria.11 The clinical outcomes included in- hos-
pital mortality and hospital length of stay (LOS).
Patients or the public were not involved in the design, 
or conduct, or reporting, or dissemination plans of our 
research.
Statistical analysis
Descriptive summary statistics are presented as mean 
values with SD for continuous variables and frequencies 
with percentages for categorical variables. Baseline char-
acteristics were compared between the elderly CDT and 
AC cohorts using an independent two- sample t test or 
two- sample Wilcoxon rank- sum test for continuous vari-
ables and using a Pearson χ2 test for categorical variables.
Clinical characteristics that were evaluated include age, 
race, body mass index (BMI), history of hypothyroidism, 
deep vein thrombosis (DVT), PE, malignancy, diabetes 
mellitus, chronic obstructive pulmonary disease, cardio-
pulmonary disease, recent surgery, current use of AC prior 
to admission, inferior vena cava filter, chronic kidney 
disease with and without need for renal replacement 
therapy, and PE severity by European Society of Cardi-
ology (ESC) classification as low risk (1), intermediate- 
to- low risk (2), intermediate- to- high risk and high risk 
(4).4 There were two outcomes of interest: (1) in- hospital 
mortality and (2) LOS. The LOS was not censored for 
in- hospital mortality.
The association between patient characteristics and 
outcome was assessed using univariate logistic regression 
with OR and corresponding 95% CIs.
We used propensity scores to construct two matched 
groups for comparative outcomes analysis. In order 
to perform propensity scores matching, we excluded 
patients who had history of malignancy or recent surgery 
and patients who had a PE severity as defined by ESC clas-
sification of low risk (1), intermediate- to low risk (2) and 
high risk (4).
For outcome analysis, we compared elderly patients 
treated with CDT versus AC. Statistical analyses were 
conducted using Stata (V. 14.0).
Table 1 Baseline patient characteristics, univariate analysis and propensity matched groups
Column
Unmatched groups Propensity matched groups
AC 108 CDT 18 P value AC 17 CDT 17 P value
Age 75.5±7.99 73.8±6.19 0.329 77.6±7.89 73.7±6.35 0.121
Caucasian 19 (41.7%) 5 (27.8%) 0.464 2 (11.7%) 5 (29.4%) 0.286
BMI (kg/m2) 28.8±8.51 33.8±7.66 0.024 30.4±12.2 33.9±7.9 0.340
Medical History
Hypothyroidism 12 (11.2%) 3 (16.7%) 0.51 1 (5.9%) 3 (17.7) 0.287
DVT 15 (14.0%) 6 (33.3%) 0.043 4 (23.5%) 6 (35.3%) 0.452
PE 10 (9.4%) 5 (29.4%) 0.018 1 (5.9%) 5 (29.4%) 0.072
Malignancy 33 (30.8%) 0 0.006 – – –
Diabetes mellitus 39 (36.5%) 3 (16.7) 0.1 7 (41.2%) 3 (17.6%) 0.132
COPD 29 (27.4%) 2 (11.1%) 0.141 6 (35.3%) 1 (5.9) 0.034
Cardiopulmonary 46 (55.4%) 8 (53.3%) 0.881 8 (66.7%) 7 (50.0%) 0.391
Recent surgery 23 (21.5%) 0 0.029 – – –
AC use 11 (10.3) 1 (5.6%) 0.529 2 (11.8%) 1 (5.9%) 0.545
IVC filter 3 (2.8%) 2 (11.1%) 0.096 1 (5.9%) 2 (11.8%) 0.545
CKD 17 (15.9%) 2 (11.1%) 0.601 3 (17.7%) 2 (11.8%) 0.628
ESRD on RRT 4 (3.7%) 0 0.404 1 (5.9%) 0 0.31
PE severity (ESC)
  1 23 (21.5%) 0 <0.001 0 0 –
  2 43 (40.2%) 0 0 0
  3 38 (35.5%) 18 (100%) 17(100%) 17(100%)
  4 3 (2.8%) 0 0 0
Bold font indicates statistical significance
AC, anticoagulation; BMI, body mass index; CDT, catheter directed thrombolysis; CKD, chronic kidney disease; COPD, chronic obstructive 
pulmonary disease; DVT, deep vein thrombosis; ESC, European Society of Cardiology; ESRD, end- stage renal disease; IVC, inferior vena 
cava; PE, Pulmonary embolism; RRT, renal replacement therapy.
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RESULTS
We identified 138 (39.9%) patients who were 65 years 
and older out of the 346 consecutive patients in the PERT 
database. The mean (SD) age was 75.3 (7.2) years, 56.5% 
were females, 19% were Caucasian. Among those identi-
fied, 108 (85.7%) patients were treated with AC and 18 
patients (14.3%) with CDT. Baseline clinical characteris-
tics of the patients are shown in table 1.
All 18 patients in the CDT cohort had intermediate- 
to- high risk (3) PE as compared with 38.7% of patients 
in the non- CDT cohort (p<0.001). Baseline clinical char-
acteristics of the CDT cohort are shown in table 2. The 
overall mortality in the elderly cohort was 6.3%. All- cause 
mortality in CDT compared with AC cohorts was 11.1% 
and 5.6% respectively (p=0.37).
Univariate analysis of clinical characteristics showed 
that patients treated with CDT compared with AC had 
significant comorbidities including BMI (28.8 vs 33.8, 
p=0.024), histories of DVT (14% vs 33.3%, p=0.043), PE 
(9.4% vs 29.4%, p=0.018) or malignancy (30.8% vs 0%, 
p=0.006), recent surgery (21.5% vs 0%, p=0.029) and PE 
severity score (p<0.001) (table 1).
In- hospital mortality was not different in the CDT 
cohort compared with the AC cohort (OR (95% CI) 2.15 
(0.394 to 11.457), p=0.381). The median LOS for the 
CDT vs AC cohort were 3.81 and 5.02 days respectively 
(p=0.540).
Baseline characteristics for the propensity- matched 
cohort are listed in table 1 and show no significant differ-
ences between the two groups, suggesting good- quality 
match.
The results in the propensity- matched cohort showed 
no difference for in- hospital mortality for the CDT group 
(5.88% vs 11.76%, p=0.545). Additionally, the median 














78 Female BiPAP Intermediate high No Bilateral 12 mg Yes Yes SNF
75 Female NRB Intermediate high Yes Bilateral 16 mg No No Deceased
84 Female 4 L/min Intermediate high Yes Unilateral 20mg Yes No SNF
79 Female 6 L/min Intermediate high Yes Bilateral 12 mg Yes No Home
77 Female 10 L/min Intermediate high No Unilateral6mg Yes No Home
73 Male 6 L/min Intermediate high Yes Bilateral; 12 mg Yes No Home
73 Female 4 L/min Intermediate high Yes Bilateral 12 mg Yes No Home
69 Female 0 L/min Intermediate high Yes Bilateral 12 mg Yes No Home
68 Female 0 L/min Intermediate high No Bilateral 12 mg Yes No Home
67 Male 0 L/min Intermediate high Yes Bilateral 24 mg Yes No Home
66 Male 0 L/min Intermediate high No Bilateral 24 mg Yes No Home
65 Male 0 L/min Intermediate high – Bilateral 24 mg Yes No Home
66 Female 2 L/min Intermediate high Yes Bilateral 12 mg Yes No Home
71 Male 2 L/min Intermediate high Yes Bilateral 12 mg Yes No Home
76 Male 3 L/min Intermediate high Yes Bilateral 24 mg Yes No Home
76 Female 0 L/min Intermediate high No Bilateral 12 mg Yes No SNF
83 Male 2 L/min Intermediate high No Bilateral 12 mg No No Deceased
83 Male 2 L/min Intermediate high Yes Unilateral 6 mg Yes No SNF
*CDT details: unilateral versus bilateral catheter placement in the pulmonary artery catheters and total tPA dose.
BIPAP, bilevel positive airway pressure; CDT, catheter directed thrombolysis; DVT, deep vein thrombosis; ESC, European Society of 
Cardiology; ISTH, International Society on Thrombosis and Hemostasis; NRB, non- rebreather; PE, pulmonary embolism; SNF, skilled nursing 
facility; tPA, tissue plasminogen activator.
Table 3 Bleeding complication, survival and follow- up for 
patients receiving CDT
CDT discharge outcome n (%)
Bleeding after tPA*
Gastrointestinal bleed 1 (5.6)
Survival at discharge 16 (88.9)
Outpatient follow- up† 12 (66.7)
Death from any cause within 30 days 2 (11.1)
Rehospitalisation within 30 days 0
Supplemental oxygen therapy at discharge 1 (5.6)
*Major bleeding was evaluated and defined using the International 
Society on Thrombosis and Hemostasis criteria.
†Four patient were outside referrals and followed up at their 
respective institutions.
CDT, catheter directed therapy; tPA, tissue plasminogen activator.
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LOS for the CDT versus AC cohort were 3.76 and 4.21 days 
(p=0.77) after matching. Postprocedure adverse effect 
and outpatient follow- up information listed in table 3.
DISCUSSION
In this study, elderly patients with mean age of 75 years 
with intermediate- risk PE were treated with CDT as 
compared with systemic AC. The CDT cohort had signif-
icantly higher comorbidities including BMI, histories of 
DVT, PE or malignancy, recent surgery and PE severity 
scores. Even with a more moribund patient popula-
tion, there was no statistically significant difference 
when comparing in- hospital mortality (p=0.545) and 
LOS (p=0.77) among the two cohorts after propensity 
matching. There were two major bleeding events per 
ISTH criteria and two fatalities in the CDT cohort but 
all- cause mortality in CDT compared with AC cohorts was 
not statistically significant.
Optimal management remains uncertain for elderly 
patients ≥65 years as they have a higher 30- day and 90- day 
mortality rates of 14.2% and 20.8%, respectively, as well as 
higher risk of bleeding compared with younger patients 
(2.5% vs 0.9%).1 3 5 6
Systemic thrombolysis is another intervention that 
is under investigation but is not recommended in the 
management of intermediate risk PE because the risk 
of life- threatening bleeding complications outweighs 
the benefits of therapy.4 12 The PEITHO trial is a large 
randomised control trial that found increased risk of 
major bleeding in a nonelderly cohort which offsets 
the benefits of therapy.5 A subgroup analysis of patients 
older than 65 years old had higher risk of bleeding events 
(12.93% vs 4.10%, p<0.001). There is limited published 
data on treatment options and associated morbidity and 
mortality for elderly patients with intermediate- risk PE 
using CDT therapy.
The mean age for our CDT cohort was 75 years 
whereas the average age in published clinical trials from 
ULTIMA, SEATTLE II, PERFECT and OPTALYSE were 
59–63 years.7–10 In our CDT cohort, 10 patients (55.6%) 
were treated with total tissue plasminogen activator 
(tPA) dose of 12 mg. The remaining eight patients were 
treated with variable total doses ranging from 6 to 24 
mg. The ULITMA trial infused 10 mg of tPA per lung 
and SEATTLE II infused 24 mg tPA.7 8 The OPTALYSE 
trial had different regimens including 4 mg for 2 hours, 
4 mg for 4 hours, 6 mg for 6 hours and 12 mg for 6 hours. 
Reported bleeding rates in published literature with CDT 
studies include up to 10% and ours was 5.6%.7 8 10 Each 
study used a different definition of bleeding.7 8 10
We had two patient deaths that occurred 24 hours 
post- CDT procedure. In- hospital death for ULTIMA, 
SETTLE II and OPTLAYSE trials are zero, three patients 
and one patient, respectively.7 8 10 All these trials enrolled 
both low- risk PEs and high- to- intermediate risk PEs, while 
our study only included high- intermediate risk PEs.
The patient who experienced major bleeding in our 
CDT cohort was a 78- year- old woman who developed a 
diverticular bleed post- treatment that required transfu-
sions and self- resolved without intervention.
Out of the two patients who expired, one was a 
75- year- old woman that developed massive haemop-
tysis from right lower lob pulmonary artery rupture 
likely predisposed by her history of chronically elevated 
haemidiaphragm 3 hours after catheter placement.13The 
other patient was an 83- year- old man who underwent 
CDT with a total tPA dose of 12 mg administered over 
6 hours who deteriorated and subsequently had pulseless 
electrical activity arrest.
In our study, patients who survived were asymptom-
atic and had minimal oxygen dependence postpro-
cedure with 15 out of 18 patients being oxygen- free at 
discharge. Most patients were discharged to home and 
had no 30- day readmission. At the follow- up, patients 
remained oxygen- free and had overall good functional 
status. Overall, there was greater than 93% survival rate 
with associated clinical improvement.
Some strengths of our study include collecting 
data on a patient cohort who are generally sicker 
with increased comorbidities. We demonstrate robust 
statistical matching using propensity score- matched 
analysis and univariate analysis for comparison 
between cohorts. A rapid assessment of patients by a 
PERT team is critical in elderly patients with acute PE. 
AC is the cornerstone management of these patients; 
however, if deterioration occurs despite AC therapy, 
CDT is a relatively safe and effective approach that 
rapidly restores RV function. We hope that multi-
centre cohort studies from high- volume centres will 
allow for more reliable conclusions on the efficacy of 
CDT in treating acute PE in the elderly. Our results 
must be interpreted in context of the study limitations 
including a small size and retrospective data from a 
single academic tertiary medical centre.
CONCLUSION
This retrospective observational study shows that 
elderly patients have similar in- hospital mortality 
and LOS when treated with CDT versus anticoagu-
lation alone. In elderly patients who have high- to- 
intermediate risk acute PE and are candidates for 
interventional therapy, CDT may be a safe alternative 
treatment modality. These findings will need to be 
confirmed in randomised controlled trial like Pulmo-
nary Embolism Thrombus Removal With Adjunctive 
Catheter- Directed Therapy (PE- TRACT) trial.
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